Follow the 리브스메드 stock price and the full management transaction log of the company, a listed issuer based in South Korea. Shares are quoted on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 리브스메드 has logged 21 public disclosures. Market capitalisation: €913.2bn. The latest transaction was reported on 22 April 2026 (Purchase). Among the most active insiders: 스톤브릿지벤처스. Every trade is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
21 of 21 declarations
리브스메드 operates in the healthcare and pharmaceutical sector, listed on the XKRX market. The company focuses on developing innovative solutions for healthcare.